Earnings Feed
Start Free
Home/Filings/4/0001104659-17-023841
4//SEC Filing

Sorrento Therapeutics, Inc. 4

Accession 0001104659-17-023841

CIK 0000850261operating
View on SEC.govCompany Profile

Filed

Apr 16, 8:00 PM ET

Accepted

Apr 17, 9:59 PM ET

Size

29.7 KB

Accession

0001104659-17-023841

Insider Transaction Report

Form 4
Period: 2017-04-13
Sorrento Therapeutics, Inc.SRNE
ABG SRNE Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441
Ally Bridge Group Capital Partners II, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
Holdings

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242
Yu Fan
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540
Ally Bridge LB Management Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
Holdings

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432
ABG Management Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242
Li Bin
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
Holdings

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242
Ally Bridge Group Innovation Capital Partners III, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441
Ally Bridge LB Healthcare Master Fund Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242
ABG II-SO Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,000,000$2,000,000→ 1,397,853 total(indirect: Through ABG II-SO Limited)
  • Purchase

    Common Stock

    2017-04-13$2.00/sh+1,500,000$3,000,000→ 1,500,000 total(indirect: Through ABG Innovation-SO Limited)
Holdings

  • Warrants

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
    432,432

  • Common Stock

    (indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
    1,441,441

  • Warrants

    (indirect: Through ABG SRNE Limited)
    Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
    540,540

  • Common Stock

    (indirect: Through ABG SRNE Limited)
    3,243,242
Footnotes (10)
  • [F1]The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
  • [F10]The warrants are exercisable at any time on or after June 7, 2016.
  • [F2]The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) ABG Innovation-SO Limited ("ABG Innovation"), a British Virgin Islands limited company,
  • [F3](ix) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (x) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
  • [F4]Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
  • [F5]ABG II-SO directly owns 1,397,853 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  • [F6]ABG LB directly owns (i) 1,441,441 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
  • [F7]ABG SRNE directly owns (i) 3,243,242 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  • [F8]ABG Innovation directly owns 1,500,000 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG Innovation, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
  • [F9]The warrants are exercisable at any time on or after May 31, 2016.

Documents

1 file

Issuer

Sorrento Therapeutics, Inc.

CIK 0000850261

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000850261

Filing Metadata

Form type
4
Filed
Apr 16, 8:00 PM ET
Accepted
Apr 17, 9:59 PM ET
Size
29.7 KB
View on SEC.gov